Abstract 148P
Background
The purpose of this study was to compare Capecitabine and Oxaliplatin (XELOX) with S-1, based on disease-free survival (DFS) and overall survival (OS) in gastric cancer (GC). In addition, clinical impact of using lymph node ratios and compare it with N stage was investigated.
Methods
Patients who had curative resection and received either S-1 or XELOX as adjuvant chemotherapy for advanced gastric cancer between Jan, 2011 and Dec, 2015, were analysed. Of the 412 patients enrolled, 301 received S-1 and 111 received XELOX. Lymph node ratio (LNR) groups were segregated as 0, 0-0.1, 0.1-0.25, and > 0.25 and named LNR 0,1,2 and 3, respectively. Propensity score matching (PSM) was used to minimize the influence of potential selection bias. The PSM compared DFS and OS in the two treatment groups, and enabled subgroup analysis according to clinical variables including the lymph node ratio group (LNR group) and N stage.
Results
In PSM cohort, the sample size of each group was 86 patients and variables are well balanced. The XELOX group showed significantly better DFS (26.9% vs 59.3%, HR 0.43, 95% CI 0.20-0.90; p = 0.025) and better OS(30.8% vs 63.0%, HR 0.44, 95% CI 0.20-0.99; 0.045) in stage IIIC. The XELOX group showed significantly better DFS in all stage III. (54.7% vs 61.6%, HR 0.57 ,95% CI 0.33-0.99; p = 0.045). The N3 group showed significantly better DFS (40% vs 65.8%, HR 0.45, 95% CI, 0.23-0.86; p = 0.017) and better OS (44.7% vs 68.4%, HR 0.48, 95% CI, 0.24-0.97; p = 0.040) in the XELOX group. The LNR 3 group showed significantly better DFS in the XELOX group (26.3% vs 52.9% with HR 0.41 (95% CI, 0.17-0.97; p = 0.042).
Conclusions
Our data suggested that current N staging and LNR could be a useful tool for selecting patients who can benefit from adjuvant XELOX after D2 gastrectomy when compared with S-1. When patients who are designated N3 or LNR > 0.25 or at stage IIIC, XELOX should be recommended over S-1.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract